R2

Cancer Treatment Is an Endurance Event. Stop Waiting for Patients to Lose Function.

A Licensing Deal Is Not Access. But It Decides Whether Access Is Possible.

COVID Vaccines Still Kept Adults Out of Hospital. The Evidence Should Matter.

Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.

When Brain Surgery Is Too Risky, Patients Still Need a Molecular Answer

Kenya Moves to Keep Cancer From Bankrupting Families

Germany Is Paying the Price for Leaving Tardive Dyskinesia Behind

A Rare Childhood Ataxia Gets Real Phase III Evidence

A Year of Measles in Utah Is What Lost Protection Looks Like
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
